Overview

* Enovis ( ENOV ) Q3 sales grow 9%, beating analyst expectations

* Adjusted EPS for Q3 beats consensus

* Company raises full-year 2025 adjusted EBITDA and EPS guidance

Outlook

* Enovis ( ENOV ) expects 2025 revenue between $2.24 bln and $2.27 bln

* Revenue guidance adjusted due to $15 mln reduction from Dr. Comfort divestitur

* Company raises full-year 2025 adjusted EBITDA guidance to $395-405 mln

* Enovis ( ENOV ) increases full-year 2025 adjusted EPS guidance to $3.10-3.25

Result Drivers

* RECONSTRUCTIVE SALES - Reconstructive sales grew 12% year-over-year, driven by stable markets and new product momentum

* GOODWILL IMPAIRMENT - Net loss impacted by a $548 mln non-cash goodwill impairment charge in Recon and P&R units

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $548.91 $538.50

Sales mln mln (11

Analysts

)

Q3 Beat $0.75 $0.65

Adjusted (11

EPS Analysts

)

Q3 Gross 59.90%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Enovis Corp ( ENOV ) is $52.50, about 40% above its November 5 closing price of $31.49

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)